Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure

Xuan Li 1
Elizabeth R. Flynn 1
Jussara M do Carmo 1
Zhen Wang 1
Alexandre A da Silva 1
Alan J Mouton 1
Ana C. M. Omoto 1
Michael E Hall 1
John E. Hall 1
Publication typeJournal Article
Publication date2022-05-12
scimago Q1
wos Q2
SJR0.975
CiteScore5.5
Impact factor2.9
ISSN2297055X
Cardiology and Cardiovascular Medicine
Abstract

Clinical trials showed that sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of drugs developed for treating diabetes mellitus, improve prognosis of patients with heart failure (HF). However, the mechanisms for cardioprotection by SGLT2 inhibitors are still unclear. Mitochondrial dysfunction and oxidative stress play important roles in progression of HF. This study tested the hypothesis that empagliflozin (EMPA), a highly selective SGLT2 inhibitor, improves mitochondrial function and reduces reactive oxygen species (ROS) while enhancing cardiac performance through direct effects on the heart in a non-diabetic mouse model of HF induced by transverse aortic constriction (TAC). EMPA or vehicle was administered orally for 4 weeks starting 2 weeks post-TAC. EMPA treatment did not alter blood glucose or body weight but significantly attenuated TAC-induced cardiac dysfunction and ventricular remodeling. Impaired mitochondrial oxidative phosphorylation (OXPHOS) in failing hearts was significantly improved by EMPA. EMPA treatment also enhanced mitochondrial biogenesis and restored normal mitochondria morphology. Although TAC increased mitochondrial ROS and decreased endogenous antioxidants, EMPA markedly inhibited cardiac ROS production and upregulated expression of endogenous antioxidants. In addition, EMPA enhanced autophagy and decreased cardiac apoptosis in TAC-induced HF. Importantly, mitochondrial respiration significantly increased in ex vivo cardiac fibers after direct treatment with EMPA. Our results indicate that EMPA has direct effects on the heart, independently of reductions in blood glucose, to enhance mitochondrial function by upregulating mitochondrial biogenesis, enhancing OXPHOS, reducing ROS production, attenuating apoptosis, and increasing autophagy to improve overall cardiac function in a non-diabetic model of pressure overload-induced HF.

Found 
Found 

Top-30

Journals

1
2
3
4
Frontiers in Cardiovascular Medicine
4 publications, 10.81%
International Journal of Molecular Sciences
4 publications, 10.81%
Life
2 publications, 5.41%
Biomedicines
2 publications, 5.41%
Cells
2 publications, 5.41%
Nature Reviews Cardiology
1 publication, 2.7%
Circulation
1 publication, 2.7%
International Immunopharmacology
1 publication, 2.7%
Metabolism: Clinical and Experimental
1 publication, 2.7%
Open Heart
1 publication, 2.7%
European Heart Journal
1 publication, 2.7%
Antioxidants
1 publication, 2.7%
FASEB BioAdvances
1 publication, 2.7%
Biomedicine and Pharmacotherapy
1 publication, 2.7%
JACC CardioOncology
1 publication, 2.7%
Molecular Medicine Reports
1 publication, 2.7%
Current Hypertension Reports
1 publication, 2.7%
Molecular and Cellular Biochemistry
1 publication, 2.7%
JACC: Heart Failure
1 publication, 2.7%
Physiology
1 publication, 2.7%
Hypertension Research
1 publication, 2.7%
Journal of Clinical Investigation
1 publication, 2.7%
European Journal of Medicinal Chemistry
1 publication, 2.7%
British Journal of Pharmacology
1 publication, 2.7%
Frontiers in Endocrinology
1 publication, 2.7%
Current Heart Failure Reports
1 publication, 2.7%
Critical Care
1 publication, 2.7%
Circulation: Heart Failure
1 publication, 2.7%
1
2
3
4

Publishers

2
4
6
8
10
12
MDPI
11 publications, 29.73%
Springer Nature
6 publications, 16.22%
Elsevier
6 publications, 16.22%
Frontiers Media S.A.
5 publications, 13.51%
Ovid Technologies (Wolters Kluwer Health)
2 publications, 5.41%
Wiley
2 publications, 5.41%
BMJ
1 publication, 2.7%
Oxford University Press
1 publication, 2.7%
Spandidos Publications
1 publication, 2.7%
American Physiological Society
1 publication, 2.7%
American Society for Clinical Investigation
1 publication, 2.7%
2
4
6
8
10
12
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
37
Share
Cite this
GOST |
Cite this
GOST Copy
Li X. et al. Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure // Frontiers in Cardiovascular Medicine. 2022. Vol. 9.
GOST all authors (up to 50) Copy
Li X., Flynn E. R., do Carmo J. M., Wang Z., da Silva A. A., Mouton A. J., Omoto A. C. M., Hall M. E., Hall J. E. Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure // Frontiers in Cardiovascular Medicine. 2022. Vol. 9.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.3389/fcvm.2022.859253
UR - https://doi.org/10.3389/fcvm.2022.859253
TI - Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
T2 - Frontiers in Cardiovascular Medicine
AU - Li, Xuan
AU - Flynn, Elizabeth R.
AU - do Carmo, Jussara M
AU - Wang, Zhen
AU - da Silva, Alexandre A
AU - Mouton, Alan J
AU - Omoto, Ana C. M.
AU - Hall, Michael E
AU - Hall, John E.
PY - 2022
DA - 2022/05/12
PB - Frontiers Media S.A.
VL - 9
PMID - 35647080
SN - 2297-055X
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@article{2022_Li,
author = {Xuan Li and Elizabeth R. Flynn and Jussara M do Carmo and Zhen Wang and Alexandre A da Silva and Alan J Mouton and Ana C. M. Omoto and Michael E Hall and John E. Hall},
title = {Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure},
journal = {Frontiers in Cardiovascular Medicine},
year = {2022},
volume = {9},
publisher = {Frontiers Media S.A.},
month = {may},
url = {https://doi.org/10.3389/fcvm.2022.859253},
doi = {10.3389/fcvm.2022.859253}
}